<scp>MTARC1</scp> Inactivation Remodels Lipid Droplets to Protect Against Metabolic Fatty Liver Disease
Our findings identify an MTARC1-GPL biosynthesis-LD degradation axis as a key regulator of hepatic triglyceride homeostasis and highlight MTARC1 inhibition as a promising therapeutic strategy for MASLD.
Authors
- Hongyu Bao
- Mengyue Wu
- Irfan Lodhi
- Shao-min Song
- Tianheng Zhao (ORCID: https://orcid.org/0000-0002-2705-0329)
- Meng Tie (ORCID: https://orcid.org/0000-0002-3488-3759)
- Jin Li (ORCID: https://orcid.org/0000-0002-6131-456X)
- Wenjing Wang (ORCID: https://orcid.org/0000-0002-4527-1168)
- Qihan Zhu
- Anyuan He
- Yong Chen (ORCID: https://orcid.org/0009-0003-8936-8150)
- Yali Chen (ORCID: https://orcid.org/0009-0007-7829-8002)
- Delong Yuan
- Juan Yu
- Xiuyun Wang
- Liwei Hu
- Peng Xu
- Yunzhi Yang
Institutions
- Anhui Medical University (CN)
- Washington University in St. Louis (US)
Publication Details
- Journal
- Liver International
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1111/liv.70539
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00